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It has long been known that oral or intravenous administration of phosphate salts lowers the serum calcium concentration in normal animals (1, 2) and in hypercalcemic human subjects (3) (4) (5) . Re- cently, interest has been renewed in the clinical use of phosphate therapy to control life-threatening hypercalcemia because of the relative ineffectiveness or toxicity of other modes of therapy (6, 7) . In 1962, Dent (5) reported dramatic lowering of the serum calcium concentration in a patient with hyperparathyroidism during the intravenous infusion of sodium phosphate and sustained lowering of serum calcium by continuing oral doses of phosphate in another patient with hyperparathyroidism. Since then, Goldsmith and Ingbar (8) have demonstrated the clinical effectiveness and apparent safety of both oral and intravenous phosphate therapy in the management of hypercalcemia accompanying a variety of diseases.
Most of the investigators who have shown that phosphate administration lowers serum calcium concentration have suggested that this effect is the result of the precipitation of calcium phosphate salts in the body. The present studies were carried out to further test this hypothesis.
If phosphate infusion lowers serum calcium concentration by causing calcium phosphate salt precipitation, then. a) phosphate infusion should tend to lower serum calcium concentration in all subjects, regardless of the presence or absence of those endocrine organs normally involved in the regulation of the serum calcium; b) a simultaneous increase in calcium excretion should not account for the fall in serum calcium occurring during phosphate infusion; and c) the degree by which serum calcium concentrations fall should be a function of the extent to which the solubility product of some calcium phosphate salt is exceeded during the infusion of phosphate.
The results of the present experiments satisfy all of these postulates and strongly support the hypothesis that phosphate infusion lowers serum calcium concentration as a result of CaHPO4 precipitation. Methods
Studies were carried out in 22 patients divided into four groups: 1) eight control subjects without disorders of calcium homeostasis, 2) three patients with hypoparathyroidism on adequate calcium and vitamin D therapy, 3) four patients with primary hyperparathyroidism, and 4) seven patients with hypercalcemia in association with malignant tumors of the breast or lung or with multiple myeloma. All were hospitalized in the Marquette University Clinical Research Center, where they received constant diets. Calcium and phosphorus intakes were constant for each subject but varied from subject to subject, ranging from 10 to 26 mmoles of calcium per day and 24 to 46 mmoles of phosphorus per day.
Venous blood pH, serum [HCO3-], and the serum concentrations of calcium, magnesium, phosphorus, and creatinine were measured serially in each subject, Three general protocols were followed: 1) Complete metabolic balance studies for calcium, phosphorus, and magnesium were carried out in one normal subject, one patient with hypoparathyroidism, and two patients with hyperparathyroidism. Observations were made during one 6-day control period and then during a 9-day experimental period. The phosphate infusion was given on the third day of the experimental period to obviate the possibility of the phosphate infusion causing excretion of calcium into the feces distal to the carmine marker used to discriminate the stool periods. 2) Urinary calcium, phosphorus, magnesium, and creatinine were measured on 2 to 6 control days, the day of phosphate infusion, and 3 to 6 recovery days in four normal subjects, two patients with hypoparathyroidism, and two patients with hyperparathyroidism as well as three patients with cancer and hypercalcemia. 3) Measurements of blood and serum constituents alone were made during 2 to 3 control days, the day of phosphate infusion, and 3 to 5 recovery days in three normal subj ects and four patients with malignant disease and hypercalcemia.
After control observations, each subject was infused with 1 to 2. The lower portion of Table I gives the mean control urinary calcium, phosphorus, and magnesium excretion rates and 24-hour endogenous creatinine clearance for those patients in each group in whom these observations were made. Urinary calcium excretion was, on the average, at the upper limits of normal in the patients with treated hypoparathyroidism and increased in the patients with hyperparathyroidism and the patients with cancer. Many of the patients with malignant diseases were anorectic and were therefore given less food than the patients in the other groups. This probably accounts for the lower urinary phosphorus excretion in the patients with cancer. Urinary magnesium excretion was comparable in all groups. Figure 1 shows the mean serum total [Ca] and serum [P] for each group before, during, and at the end of phosphate infusion. Data for each individual subject are presented in Table II . As shown in Figure 1 and Table II [Ca] returned to the control levels 30 hours after the infusion was completed.
As shown in Table III urinary calcium excretion declined in each of 15 subjects after phosphate infusion. For the group, urinary calcium fell significantly from an average of 7.4 + 5.6 mmoles per day during control to 3.4 ± 2.6 and 3.4 + 3. mmoles per day on the day of and the day after phosphate infusion, respectively.
As shown in Table IV fecal calcium did not increase. Instead, a small decrease was found in three of the four subjects whose stools were analyzed. For the group fecal calcium declined from 15.8 + 14.0 mmoles per day during control to 12.3 + 10.2 mmoles per day in the metabolic period during which phosphate was infused. Figure 3 shows the relationship between the mean molar product of serum ultrafilterable [Ca] times [HPO4=] during each infusion and the observed fall of total serum [Ca] in the 12 subjects of the present study in whom these measurements were made. It is known that ultrafilterable calcium is almost entirely ionized, and it has been y=4. 6 Figure 3 should be an in vivo estimate of the CaHPO, solubility product. The intercept value of 2.4 x 10-6 mole per L is in good agreement with the in vitro estimates cited. In Figure 4 , the intercept value on the ordinate of the regression line relating the fall in serum total [Ca] to the serum total [Ca] X [P] molar product is 4.6 X 10-6 mole per L. If this intercept value is expressed in miligrams per 100 ml, its numerical value becomes 58 and is in close agreement with the figure of 60 estimated by Albright and Reifenstein to represent the saturation point of serum with respect to calcium and phosphorus (15) .
An earlier suggestion that elevation of the serum phosphorus lowered serum calcium only in hypercalcemic patients (16) was not confirmed, since the serum total [Ca] of normal subjects also fell during phosphate infusion in the present studies (Table II) . Serum total [Ca] also fell in three patients with hypoparathyroidism, one of whom had a total thyroparathyroidectomy, and in three patients with breast cancer who had both adrenals and ovaries removed. These findings, taken with the fact that phosphate infusion could be shown to lower serum calcium within 3 minutes, lead us to conclude that hormonal factors are not involved in the reduction of. serum calcium that occurs during phosphate infusion. All of our data are consistent with the interpretation that phosphate lowers serum [Ca] by simple physicochemical precipitation of CaHPO4 as its solubility product is exceeded.
The site or sites at which CaHPO4 precipitation occurs is of obvious clinical importance. Albright, Bauer, Claflin, and Cockrill (4) and Dent (5) cautioned that phosphate administered to hypercalcemic patients might result in soft tissue calcification or kidney stone formation. The studies of Gersh (17) suggest that calcium phosphate salts precipitate in the vascular system but are rapidly removed by macrophages in liver, spleen, and bone marrow and then presumably are slowly released again into the circulation. Goldsmith and Ingbar found extraskeletal calcifications at autopsy in several patients who had received phosphate (8) . Calcium deposition in the vein into which phosphate was infused was noted roentgenologically in three of our patients with cancer and hypercalcemia. It is certainly also conceivable that as the CaHPO4 molar product increases, the net rate of release of calcium from bone decreases. Further studies of this possibility will be required.
The small reductions in serum [Mg] that occurred during phosphate infusion did not appear to be determined by a [Mg] x [P] molar product, but rather, they appeared to correlate with the magnitude of the reduction in serum [Ca] (Figure 7 ). This suggests that magnesium may coprecipitate with CaHPO4.
Since serum [P] had returned to control values within 24 hours after the phosphate infusion, the CaHPO4 solubility product was no longer exceeded in any subject beyond this time. Thus, other mechanisms must account for the delayed return of serum [Ca] to control levels in the patients with hypoparathyroidism, hyperparathyroidism, and cancer as compared to the normal subjects. In part, the apparent delay in the hypercalcemic patients was related to the higher control [Ca] . However, there is indirect evidence that the capacity to increase parathyroid hormone secretion may also have played a role. In the normal subjects two kinds of observations during and after phosphate infusion suggested a prompt increase in parathyroid hormone secretion in response to the reduction in serum [Ca] during infusions. First, although the greatly augmented filtered load of phosphate during infusion would have been expected to increase the absolute rate of tubular phosphate reabsorption (18) , only a very slightly increased reabsorption was actually found during the infusion, and tubular phosphate reabsorption was significantly below control during the first recovery day (Figure 6 ). Second, during the first recovery day, urinary calcium excretion was less than control despite the fact that serum [Ca] had returned to, or even above, control levels. As would be expected in the absence of parathyroid function, the patients with hypoparathyroidism showed a sharp increase in tubular phosphate reabsorption during infusion. Similarly, the hypercalcemic patients also had marked increases in tubular phosphate reabsorption during phosphate infusion, which suggests a delayed response of the parathyroids to the induced fall of serum [Ca] .
Clearly, lowering of serum [Ca] by intravascular precipitation of CaHPO4 is theoretically objectionable and potentially hazardous. The chances of significant damage to vital soft tissues by calcium precipitation are obviously a function of the total quantity of calcium precipitated and thus of the initial serum total [Ca], the total quantity of phosphate administered, and the rate at which it is infused. Because of these hazards it seems unreasonable to attempt to lower serum [Ca] to levels below which symptoms of calcium intoxication generally do not occur (about 3.0 mmoles per L). If an appropriate quantity of phosphate is infused over a 6-hour period, the present results suggest that symptomatic improvement can be attained without significant toxicity. The subsequent response to the fall in serum calcium levels induced by phosphate infusion appeared to depend upon the presence and responsiveness of the parathyroid glands.
